Lite Strategy, Inc.

9 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Mei Pharma, Inc. (to 2026)

Ending by 2030

Jan 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 16, 2026
The maintenance fee for (Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases (US 9,056,852) comes due Dec 16, 2026. Unpaid by Jun 16, 2027, it lapses early.
1 fee due Jan 2, 2027
The maintenance fee for (Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases (US 10,335,415) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
1 fee due Sep 30, 2027
The maintenance fee for (Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases (US 10,603,324) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 8,486,939	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy In force Term ends Jan 29, 2031 · High confidence	In force	Term ends Jan 29, 2031	High confidence
US 10,064,868	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Mar 27, 2032 · High confidence	In force	Term ends Mar 27, 2032	High confidence
US 10,335,415	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Mar 27, 2032 · High confidence	In force	Term ends Mar 27, 2032	High confidence
US 10,603,324	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Mar 27, 2032 · High confidence	In force	Term ends Mar 27, 2032	High confidence
US 11,400,097	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Mar 27, 2032 · High confidence	In force	Term ends Mar 27, 2032	High confidence
US 12,059,422	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Mar 27, 2032 · High confidence	In force	Term ends Mar 27, 2032	High confidence
US 9,056,852	(Alpha-Substituted Aralkylamino and Heteroarylalkylamino) Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles, Pharmaceutical Compositions Thereof, and Their Use in Treating Proliferative Diseases In force Term ends Dec 2, 2032 · High confidence	In force	Term ends Dec 2, 2032	High confidence
US 11,304,953	Combination Therapy In force Term ends May 22, 2038 · High confidence	In force	Term ends May 22, 2038	High confidence
US 12,161,644	Combination Therapy In force Term ends May 22, 2038 · High confidence	In force	Term ends May 22, 2038	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro